2011
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals Of Surgical Oncology 2011, 19: 1508-1516. PMID: 22193884, DOI: 10.1245/s10434-011-2108-2.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic therapyPrimary breast cancerBreast cancerSystemic therapyBreast-conserving surgery rateLarge adjuvant trialsPathologic complete responseInflammatory breast cancerNew therapeutic regimensIntermediate end pointsInternational Consensus ConferenceClinical research groupAdjuvant trialsNew regimensPathologic responseComplete responseSurgery ratesTherapeutic regimensConsensus conferenceEnd pointTherapyCancerTrialsRegimensPanel of representatives
2010
The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis.
Alvarez R, Bianchini G, Hsu L, Cristofanilli M, Esteva F, Pusztai L, Buzdar A, Hortobagyi G, Valero V. The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis. Journal Of Clinical Oncology 2010, 28: 548-548. DOI: 10.1200/jco.2010.28.15_suppl.548.Peer-Reviewed Original Research
2009
Triple-negative breast cancer—current status and future directions
Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer—current status and future directions. Annals Of Oncology 2009, 20: 1913-1927. PMID: 19901010, DOI: 10.1093/annonc/mdp492.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBasal-like breast cancerBreast cancerBreast cancer—current statusStandard cytotoxic chemotherapy regimensHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Common cytotoxic agentsCytotoxic chemotherapy regimensGrowth factor receptor 2Factor receptor 2Chemotherapy regimensClinical featuresUnfavorable prognosisProgesterone receptorLack of expressionNovel agentsReceptor 2Cytotoxic agentsPrognosisComplete concordanceCancerGene expression analysisHigh-throughput gene expression analysisRegimens
2005
Gene expression profiling of primary breast cancer
Rouzier R, Wagner P, Morandi P, Pusztai L. Gene expression profiling of primary breast cancer. Current Oncology Reports 2005, 7: 38-44. PMID: 15610685, DOI: 10.1007/s11912-005-0024-y.Peer-Reviewed Original Research
2004
Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?
Pusztai L, Rouzier R, Wagner P, Symmans WF. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Drug Resistance Updates 2004, 7: 325-331. PMID: 15790543, DOI: 10.1016/j.drup.2004.10.002.Peer-Reviewed Original ResearchConceptsChemotherapy regimensChemotherapy treatmentPatient outcomesBreast cancerClinical utilitySmall exploratory studyIndividualized selectionClinical pharmacogenomicsPredictive testUseful predictorCancerMolecular characteristicsMarker researchTranscriptional profilingRegimensValidation trialsChemotherapyTrialsTechnology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer
Pusztai L, Gianni L. Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer. Nature Reviews Clinical Oncology 2004, 1: 44-50. PMID: 16264799, DOI: 10.1038/ncponc0025.Peer-Reviewed Original ResearchConceptsBreast cancerOptimal chemotherapy regimenHistopathologic predictorsChemotherapy regimenChemotherapy regimensPreoperative chemotherapyPolymerase chain reactionPotential diagnostic toolMultiplex polymerase chain reactionClinical useGene expressionChain reactionDiagnostic toolCancerMeaningful responsesRegimenRegimensChemotherapyPatientsPrognosis